Board of Directors

Richard R. Allen
Mr.Allen has 30 years of experience in business and finance, including 16 years in executive leadership positions with technology and med-tech businesses. In 1998 Mr. Allen co-founded Regeneration Technologies, Inc. (Nasdaq:RTIX), developing the company's strategic business plan, negotiating the spin-off of the company’s underlying technology from the University of Florida, raising the initial venture capital, and leading its initial public offering in 2000.

Mr. Allen is also the founder of Synogen, a private venture fund investing in early-stage biomedical and medical device companies, and co-founder of Emergent Growth Fund, an angel investment fund. With a background in technology, business and finance, he has had responsibility for finance, business development, IT, HR, IR, technology licensing and M&A, and has negotiated several acquisitions as well as venture capital funding for several successful start-ups. He is also co-founder and director of Sustainable Cambodia, a 501(c)(3) nonprofit organization working to create a sustainable quality of life in Cambodian villages.

Jack Wilkens
Mr. Wilkens is the CEO of GeneEx, Inc., having joined the company in January 2006. Prior to GeneEx he was COO and Executive VP of Consumer Diagnostics for Inverness Medical Innovations, Inc., (IMI) Waltham, Massachusetts. IMI is the leading point-of-care rapid diagnostic company worldwide with sales over $400 million and is the world's leading company in women's health diagnostics. It is also active in the areas of infectious disease diagnosis and chronic disease monitoring such as cardiology. Prior to the COO role at IMI, Jack was the Managing Director of Unipath, a wholly owned subsidiary of IMI located in Bedford, England. During this period he led the expansion of sales in women's health diagnostics from $100 to $170 million per year and led the launch of IMI's digital pregnancy test, the world's first consumer digital diagnostic test.

From 2001 until 2003 Mr. Wilkens was Managing Director of IMI's and Johnson  Johnson's diabetes operations in Inverness, Scotland and was responsible for manufacturing, Quality and Regulatory Affairs, technical support, purchasing, capital expansion, logistics, product launch and IMI's European sales. The Scotland operation developed, manufactured and launched the world's leading blood glucose monitor and the first simple electro-chemical meter for Asia and developing countries. Sales expanded from zero to over 3 billion test strips sold today.

Prior to IMI/J&J, Wilkens was VP of Medical Imaging Systems with Sterling Diagnostics/AGFA a $275 million operation, and prior to that he worked with Polaroid Corporation in digital medical imaging, manufacturing, product development and marketing, where he was responsible for the design, construction and operation of Polaroid's digital imaging facilities. He has a BS in Chemical Engineering from Michigan State University and an MBA from Western New England College.

Mark S.Gold, M.D.
Dr. Gold has combined academic achievement with business and management expertise in a successful career in medicine, academics and finance. He is currently serving as Dizney Eminent Scholar and Distinguished Professor at the University of Florida College of Medicine's Brain Institute in the Departments of Psychiatry, Neuroscience, Anesthesiology, Community Health & Family Medicine, where he is also Interim Chair and Chief in the Division of Addiction Medicine.

Over his 35 year translational research career, Dr. Gold has done extensive laboratory and clinical research with drugs of abuse, medications, adherence and monitoring. In the field of medical technology, he is a co-inventor of technology for testing of medication Dr. Gold and his Yale colleagues pioneered and automated cocaine testing in blood and urine as well as for other drugs of abuse. adherence and compliance, and therapeutic drug monitoring for medication used to treat epilepsy and other medical conditions. Dr Gold has had considerable experience and success in developing laboratory models for addictions and then developing new treatments. He is one of a very few researchers to have patented important new uses for existing medications without a university as a co-inventor or owner of the patent, and to have then sold the patent to a major multinational pharmaceutical company for manufacture and marketing.

Dr. Gold combines his medical knowledge with many years of experience in business and finance, where he has consulted for companies such as Medtronic, Ciba-Geigy, Merck, Wyeth, Roche, Alkermes, Dupont, Glaxo, Abbott, and Forest Laboratories. He was a major investor and founding member for Aklaim Video, the company responsible for the leading video game Mortal Kombat. He was a co-founder and founding director of Somerset Valley Bank, helping the bank go from concept to its first bank opening, to a chain, to its public listing on NASDAQ and to its sale for nearly $100 million. Dr. Gold has provided consulting services to top-tier financial firms such as Goldman Sachs, Lehman Brothers, Oppenheimer, the Carlyle Group and Smith Barney, as well as currently co-authoring a subscription financial newsletter for Phillips.

As a world-renowned addiction researcher, Dr. Gold has been involved in the development of numerous new approaches which have rapidly progressed from bench-to-bedside. His research has led to changes in the treatment of physician addiction, opiate and cocaine addiction and food addiction. He is the author of twelve professional books and over 900 medical articles, chapters, and abstracts in journals for health professionals. He is frequently the expert interviewed for comment by the Wall Street Journal ,other major business, and national publications concerned with the strengths and limitations of new technology and treatments in obesity, pain, drug addiction and psychiatry.

David Dizney
David Dizney is currently President and Chief Executive Officer of Ten Broeck Healthcare and one of three shareholders of United Medical Corporation, its parent company. Founded in 1974, United Medical is one of Florida’s largest privately held corporations, which owns and operates a network of hospitals through two operating divisions based out of Windermere,Florida. Ten Broeck operates hospitals and provides management services for client hospitals specializing in acute care and behavioral services. Mr. Dizney is responsible for all operations and strategic planning.

Mr. Dizney’s diverse background in the healthcare industry spans 20 years and includes hospital operations, acquisitions, divestitures and experience in accessing credit markets including bond issuances, private equity and syndicated loans. He oversees a corporate office staff that provides central support and oversight with expertise in regulatory compliance, clinical oversight, managed care contracting, all additional third party reimbursement issues, marketing, internal auditing, and financial reporting. Mr. Dizney has been involved in numerous start-up operations and acquisitions specifically in specialty areas of healthcare delivery including reference lab development, health maintenance organizations, home health agencies, physician practices, and contract management services.

Mr. Dizney serves on the Board of Directors of United Medical Corporation, PaviaHealth Holding Company, Inc. (specialty hospitals serving the Caribbean), the Healthy Florida Foundation and Independent Banc Shares. He represents the companies with the Federation of American Hospitals and serves as the Treasurer for the National Association of Psychiatric Health Systems. A graduate of the University of South Florida with a BS in Finance, Mr. Dizney holds an MBA from the Kellogg School of Management at Northwestern University.

S. Tucker Johnson
Mr. Johnson, a member of the family that founded Johnson and Johnson (NYSE:JNJ), is a co-founder and founding director of Somerset Valley Bank and SVB Financial Services (NASDAQ:SVBF), which was acquired by Fulton Financial (NASDAQ:FULT).